Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the 10 Stocks Investors Are Buying Now.

Corcept Therapeutics rallied for a second day on Wednesday, soaring 19.66 percent to finish at $40.47 apiece, as investors snapped up shares after securing the green light of the Food and Drug Administration (FDA) to sell its ovarian cancer treatment, Lifyorli.

In an updated report, Corcept Therapeutics Inc. (NASDAQ:CORT) said that the approval was based on the success of its clinical trial, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy, including Bevacizumab.

Photo by Gustavo Fring on Pexels

During the study, the company found that patients treated with Lifyorli in combination with nab-paclitaxel experienced a 35 percent and 30 percent reduction in death risk and disease progression, respectively, as compared with those patients who took nab-paclitaxel alone.

Lifyorli was also well-tolerated, having only recorded decreased hemoglobin and neutrophils, as well as fatigue, nausea, diarrhea, decreased platelets, rash and decreased appetite, as its adverse effects.

“Today's approval of Lifyorli is an important first step, but there is much more to explore with this new mode of treatment. We extend our deep appreciation to the patients and healthcare providers who participated in the clinical trials that made this approval possible,” Corcept Therapeutics Inc. (NASDAQ:CORT) CEO Joseph Belanoff said.

Complete results from the trial are set to be presented at the Society of Gynecologic Oncology (SGO) meeting in April.

While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.